• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高危神经母细胞瘤治疗综述

High-Risk Neuroblastoma Treatment Review.

作者信息

Smith Valeria, Foster Jennifer

机构信息

Baylor College of Medicine Department of Pediatrics, Texas Children's Cancer and Hematology Center, Houston, TX 77030, USA.

出版信息

Children (Basel). 2018 Aug 28;5(9):114. doi: 10.3390/children5090114.

DOI:10.3390/children5090114
PMID:30154341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6162495/
Abstract

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification of therapy has vastly improved survival rates, and research is focused on novel treatments to further improve survival rates. The current treatment schema is divided into three stages-induction, consolidation, and maintenance. This review serves as an overview of the current treatment for high-risk neuroblastoma and a glimpse at current research for future therapy.

摘要

神经母细胞瘤是儿童最常见的颅外实体瘤。其中一个亚组,即高危神经母细胞瘤,治疗非常困难,需要多模式治疗。强化治疗已极大提高了生存率,研究集中在新型治疗方法以进一步提高生存率。目前的治疗方案分为三个阶段——诱导、巩固和维持。本综述概述了高危神经母细胞瘤的当前治疗方法,并简要介绍了未来治疗的当前研究情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc80/6162495/4e05af035ca5/children-05-00114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc80/6162495/4e05af035ca5/children-05-00114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc80/6162495/4e05af035ca5/children-05-00114-g001.jpg

相似文献

1
High-Risk Neuroblastoma Treatment Review.高危神经母细胞瘤治疗综述
Children (Basel). 2018 Aug 28;5(9):114. doi: 10.3390/children5090114.
2
Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma.高危神经母细胞瘤患者早期使用贝伐单抗。
Case Rep Pediatr. 2021 Jun 19;2021:6610955. doi: 10.1155/2021/6610955. eCollection 2021.
3
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.维甲酸巩固治疗用于接受自体造血干细胞移植的高危神经母细胞瘤患者。
Cochrane Database Syst Rev. 2015 Jan 29;1:CD010685. doi: 10.1002/14651858.CD010685.pub2.
4
Neuroblastoma: biology, prognosis, and treatment.神经母细胞瘤:生物学、预后和治疗。
Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011.
5
Neuroblastoma: biology, prognosis, and treatment.神经母细胞瘤:生物学、预后及治疗
Pediatr Clin North Am. 2008 Feb;55(1):97-120, x. doi: 10.1016/j.pcl.2007.10.014.
6
Risk-based management: current concepts of treating malignant solid tumors of childhood.基于风险的管理:儿童恶性实体瘤治疗的当前概念
J Am Coll Surg. 1999 Oct;189(4):407-25. doi: 10.1016/s1072-7515(99)00167-2.
7
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2013 Aug 22(8):CD006301. doi: 10.1002/14651858.CD006301.pub3.
8
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.迈向个体化治疗的进展:神经母细胞瘤的生物和风险导向治疗。
Expert Rev Neurother. 2011 Oct;11(10):1411-23. doi: 10.1586/ern.11.103.
9
Neuroblastoma: Therapeutic strategies for a clinical enigma.神经母细胞瘤:临床难题的治疗策略。
Cancer Treat Rev. 2010 Jun;36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006. Epub 2010 Mar 12.
10
Overview of current treatment of neuroblastoma.神经母细胞瘤当前治疗概述。
Am J Pediatr Hematol Oncol. 1992 May;14(2):97-102. doi: 10.1097/00043426-199205000-00002.

引用本文的文献

1
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.一种携带吡咯并苯并二氮杂卓有效载荷的人源化间变性淋巴瘤激酶(ALK)导向抗体药物偶联物在表达ALK的癌症中显示出疗效。
Nat Commun. 2025 Aug 15;16(1):7578. doi: 10.1038/s41467-025-62979-1.
2
AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression.AXL酪氨酸激酶抑制剂TP-0903通过靶向miR-335-3p/DKK1表达诱导活性氧触发神经母细胞瘤细胞凋亡。
Cell Death Discov. 2025 Aug 13;11(1):378. doi: 10.1038/s41420-025-02681-9.
3

本文引用的文献

1
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.基因组扩增和 6q 远端缺失:高危神经母细胞瘤患者不良生存的新标志物。
J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.
2
Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.完整手术切除可改善年龄超过18个月的INRG高危局限性神经母细胞瘤患者的预后。
BMC Cancer. 2017 Aug 4;17(1):520. doi: 10.1186/s12885-017-3493-0.
3
Incorporation of high-dose I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.
Prognostic implications of store-operated calcium entry signatures and immune dynamics in neuroblastoma via machine learning.
通过机器学习分析神经母细胞瘤中储存式钙内流特征和免疫动力学的预后意义
Transl Cancer Res. 2025 Jul 30;14(7):4179-4193. doi: 10.21037/tcr-2024-2563. Epub 2025 Jul 23.
4
Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.小儿神经母细胞瘤的治疗创新:从产前到幼儿期的年龄和阶段特异性策略——一篇综述文章
Iran J Child Neurol. 2025 Jun 25;19(3):9-29. doi: 10.22037/ijcn.v19i3.48040. eCollection 2025 Summer.
5
Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment.联合靶向PRDX6和GSTP1作为神经母细胞瘤治疗的一种潜在分化策略。
Proc Natl Acad Sci U S A. 2025 Jun 24;122(25):e2427211122. doi: 10.1073/pnas.2427211122. Epub 2025 Jun 18.
6
Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.将CD3/GD2双特异性T细胞衔接子与人Vγ9Vδ2 T细胞相结合,有助于在体外靶向和杀伤神经母细胞瘤细胞。
PLoS One. 2025 Jun 9;20(6):e0325389. doi: 10.1371/journal.pone.0325389. eCollection 2025.
7
Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death.利用CRISPR-Cas9切口酶对基因组扩增和重复元件进行选择性靶向以促进癌细胞死亡。
Nat Commun. 2025 Jun 2;16(1):5126. doi: 10.1038/s41467-025-60160-2.
8
Exploring Pediatric Neuroblastoma: A Comprehensive Analysis of Adrenal and Nonadrenal Tumor Characteristics in the United States.探索儿童神经母细胞瘤:美国肾上腺和非肾上腺肿瘤特征的综合分析
Avicenna J Med. 2025 Apr 2;15(1):1-8. doi: 10.1055/s-0045-1807243. eCollection 2025 Jan.
9
Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.抗ROR1嵌合抗原受体自然杀伤细胞与分泌白细胞介素-21的溶瘤病毒联合免疫疗法治疗神经母细胞瘤。
Mol Ther Oncol. 2024 Dec 21;33(1):200927. doi: 10.1016/j.omton.2024.200927. eCollection 2025 Mar 20.
10
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?靶向MYCN-MDM2通路进行癌症治疗:它们是否具有可药用性?
Genes Dis. 2023 Oct 27;12(2):101156. doi: 10.1016/j.gendis.2023.101156. eCollection 2025 Mar.
高危神经母细胞瘤中高剂量 I-间碘苄胍治疗与串联大剂量化疗和自体干细胞移植联合应用:SMC NB-2009 研究结果。
J Hematol Oncol. 2017 May 16;10(1):108. doi: 10.1186/s13045-017-0477-0.
4
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.白消安和马法兰与卡铂、依托泊苷和马法兰在高危神经母细胞瘤(HR-NBL1/SIOPEN)的高剂量化疗中的比较:一项国际、随机、多臂、开放标签、3 期临床试验。
Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2.
5
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.21Gy放射治疗对高危神经母细胞瘤的局部控制
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):393-400. doi: 10.1016/j.ijrobp.2016.05.020. Epub 2016 May 27.
6
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.二氟甲基鸟氨酸(DFMO)在神经母细胞瘤治疗中的转化开发。
Transl Pediatr. 2015 Jul;4(3):226-38. doi: 10.3978/j.issn.2224-4336.2015.04.06.
7
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.不同预处理方案(白消安/美法仑和卡铂/依托泊苷/美法仑)用于晚期神经母细胞瘤后的毒性比较:两个移植中心的经验
Pediatr Transplant. 2016 Mar;20(2):284-9. doi: 10.1111/petr.12638. Epub 2015 Nov 28.
8
Telomerase activation by genomic rearrangements in high-risk neuroblastoma.高危神经母细胞瘤中基因组重排导致的端粒酶激活
Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14.
9
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.克唑替尼在神经母细胞瘤临床前模型中与化疗协同作用。
Clin Cancer Res. 2016 Feb 15;22(4):948-60. doi: 10.1158/1078-0432.CCR-15-0379. Epub 2015 Oct 5.
10
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.神经母细胞瘤风险分类与治疗策略的进展
J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24.